A Swapping Method Based on Covariate Classification for Average TreatmentEffect Estimation.

A Swapping Method Based on Covariate Classification for Average Treatment Effect Estimation.

Rowena is supported by Teaching Assistantship, and the other two major researchers are self-funded.

The lead Researcher declares that he has no competing interests. Researcher 1 declares that she has no competing interests. Researcher 2 declares that she has no competing interests. The Statistician declares that he has no competing interests.

A swapping method is a novel method to improve the estimate of average treatment effect in clinical trials and observational studies. The average treatment effect is the estimated treatment effect compared to the baseline. However, the imbalance in covariates, the measures other than the treatment/baseline and the patient response, exists in non-double-blind randomized trials, and can bring in the bias in estimating the average treatment effect. Although traditional methods can remedy to the issue, the imbalance continues to be an issue.

We propose a swapping method to achieve the balance via two steps. We first classify all patients into subclasses based on discrete covariates. Within each subclass, we then calculate the average treatment effect using the better model between the treatment and baseline groups. The simulation studies show that the proposed method provides more stable estimates than traditional methods.

The applied datasets are important to help the public understand that the imbalance in covariates exists in non-double-blind randomized trials. Therefore, the powerful tools are needed to correct the bias in better estimating the average treatment effect. The effective estimate of the average treatment effect is important in making the decision on the treatment selection and the clinical trials. We provide powerful solutions and tools for estimating the average treatment effect in clinical trials and observational studies.

[{ "PostingID": 1602, "Title": "BI-1235.7", "Description": "Open Label Study Telmisartan and Amlodipine in Hypertension

Medicine: telmisartan + amlodipine, Condition: Hypertension, Phase: 3, Clinical Study ID: 1235.7, Sponsor: Boehringer Ingelheim" },{ "PostingID": 1802, "Title": "GSK-NPP30006", "Description": "Open label, safety study for use of lamictal in patients with diabetic neuropathy

Medicine: lamotrigine, Condition: Neuropathy, Diabetic, Phase: 3, Clinical Study ID: NPP30006, Sponsor: GSK" },{ "PostingID": 1965, "Title": "BI-1200.10", "Description": "An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer

Medicine: afatinib , Condition: Breast Neoplasms, Phase: 2, Clinical Study ID: 1200.10, Sponsor: Boehringer Ingelheim" }]

This proposal was superseded by Research Proposal ID 1528. Please reference https://clinicalstudydatarequest.com/Posting.aspx?ID=14439